957 results about "Pulmonary Cancers" patented technology

The disclosure provides a method for treating a subject afflicted with a tumor, e.g., derived from a non-small cell lung cancer (NSCLC), comprising administering to the subject a combination of a (a) chemotherapy, (b) an anti-PD-1 antibody or an anti-PD-L1 antibody, and (c) an anti-CTLA-4 antibody, wherein the chemotherapy is administered for a period of time that is less than the standard.

The application relates to a compound of formula (I) containing a thiazole ring, an indazol ring and a 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole ring system, to pharmaceutical compositions containing it and its medical use. The compounds are described as selective allosteric inhibitors of T790M / L858R, T790M / L858R / C797S, L858R, L858R / C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.

The disclosure provides a method of treating a human subject afflicted with lung cancer (e.g., non-small cell lung cancer (NSCLC)) with a programmed death-1 (PD-1) pathway inhibitor (e.g., an anti-PD-1 antibody) and a concurrent chemoradiotherapy (CCRT, e.g., a platinum doublet chemotherapy (PDCT) and a radiation therapy) followed by a combination of a PD-1 pathway inhibitor (e.g., an anti-PD-1 antibody) and a lymphocyte activation gene-3 (LAG-3) antagonist (e.g., an anti-LAG-3 antibody). In some aspects, the method comprises a recovery period that begins upon completion of the treatment with the PD-1 pathway inhibitor and the CCRT and ends at the start of the treatment with the combination of the PD-1 pathway inhibitor and the LAG-3 antagonist.

Disclosed herein is use of a combination of Compound (A) (azenosertib), or a pharmaceutically acceptable salt thereof, and a KRAS G12C inhibitor, such as sotorasib or adagrasib, or a pharmaceutically acceptable salt thereof, for treating a disease or condition, such as a colorectal, pancreatic and / or non-small cell lung cancer.

The invention relates to a plasma biomarker for predicting the curative effect of non-small cell lung cancer immunotherapy and application of the plasma biomarker. The biomarker for predicting the curative effect of the non-small cell lung cancer immunotherapy, disclosed by the invention, comprises phosphoglycerate kinase 1 (PGK1), fibronectin 1 (FN1), chromogranin A (CHGA), elastin (ELN), heterogeneous ribonucleoprotein H3 (HNRNPH3) and an Aly / REF output factor (ALYREF). The plasma biomarkers for predicting the non-small cell lung cancer immunotherapy curative effect can be detected by adopting a mass spectrum method, and the non-small cell lung cancer immunotherapy curative effect of a patient is judged by the markers.

The invention discloses an application of a polysaccharide monomer separated from schisandra chinensis in preparation of a PD-L1 + TAMs activator. A large number of experiments show that the polysaccharide monomer schisanan B separated from schisandra chinensis can effectively activate PD-L1 + TAMs cell subsets, so that the phagocytosis of TAMs is enhanced, and the proliferation of tumor cells is inhibited; therefore, it is determined that the polysaccharide monomer schisanan B separated from schisandra chinensis can serve as a natural PD-L1 + TAMs cell subset activator to be used for treating cancers such as non-small cell lung cancer, intestinal cancer, melanoma, urothelial carcinoma or liver cancer, and the polysaccharide monomer schisanan B has the advantages of being free of toxic and side effects, low in price, wide in adaptive patient population and the like.

The invention relates to the technical field of biological medicine, and particularly discloses a plant exovesicle combined preparation for treating non-small cell lung cancer and a preparation method and application thereof, and the plant exovesicle combined preparation comprises ginseng exovesicles and turmeric exovesicles. The plant external vesicle combined preparation provided by the invention is used for inhibiting non-small cell lung cancer cells and promoting apoptosis of the non-small cell lung cancer cells, and can be used for preparing medicines for treating the non-small cell lung cancer.

The invention relates to an application of an intervention SNRK-MTA1 signal channel axis in preparation of a non-small cell lung cancer targeted therapy drug. The nucleotide sequences of the mRNA of the SNRK gene and the mRNA of the MTA1 gene are respectively as shown in SEQ ID NO.1-2. The invention innovatively provides a strategy for treating the non-small cell lung cancer through double-target combined intervention. According to the strategy, SNRK gene expression is improved through exogenous gene overexpression plasmids, and meanwhile MTA1 gene expression is silenced through the siRNA technology. In a non-small cell lung cancer model, the strategy of combined application of the SNRK-OE plasmid and siMTA1 can specifically up-regulate the SNRK mRNA level and knock down the MTA1 mRNA level at the same time, and the combined strategy shows a better anti-tumor effect than single intervention, and can more effectively inhibit the growth and migration of tumor cells. Based on the discovery, the SNRK-MTA1 signal pathway axis can be developed into a novel therapeutic target for non-small cell lung cancer, and is used for designing a drug combination scheme or a composite targeted drug.

The present invention provides improved and / or shortened processes and methods for preparing TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy for the treatment of non-small cell lung carcinoma (NSCLC), wherein the NSCLC is refractory to treatment with an anti-PD-1 antibody and / or anti-PD-L1 antibody and / or VEGF inhibitor, or wherein the NSCLC has a predetermined tumor proportion score (TPS).

The invention relates to a biomarker combination for clinical benefit of non-small cell lung cancer immunotherapy and application of the biomarker combination. The biomarker for predicting the clinical benefit of the non-small cell lung cancer immunotherapy comprises an immune globulin kappa light chain variable region 1-27 (IGKV1-27), a human leukocyte antigen H (HLA-H), an S100 calcium binding protein A8 (S100A8), a chromogranin A (CHGA), an elastin (ELN) and a nephronectin (NPNT). The biomarkers for predicting the clinical benefit of the immunotherapy of the non-small cell lung cancer can be detected, and the clinical benefit effect of the immunotherapy of the non-small cell lung cancer of a patient is judged by the markers.

The invention relates to the technical field of medical artificial intelligence, and discloses a non-small cell lung cancer immunotherapy risk assessment method and system and a storage medium, and the method comprises the steps: constructing an optimal strategy tree model capable of dividing a patient into a plurality of subgroups based on a historical patient data set, and determining an initial optimal treatment strategy for each subgroup; determining a subgroup to which a new patient belongs and an initial treatment strategy thereof according to the model; in the treatment process, the deviation degree between the individual response trajectory of the patient and the average response trajectory of the subgroup to which the individual response trajectory belongs is calculated; and when the deviation degree exceeds a preset threshold value of the subgroup, triggering an adaptive adjustment mechanism, and outputting an updated treatment suggestion. By establishing a dynamic monitoring and closed-loop feedback mechanism based on the subgroup benchmark, the technical problem that an existing scheme is difficult to carry out prospective identification and dynamic intervention on individualized risks is solved, so that the accuracy, safety and individualized level of non-small cell lung cancer immunotherapy are improved.

The invention provides a non-small cell lung cancer auxiliary diagnosis composition and application and a kit thereof, and relates to the technical field of biological detection.The non-small cell lung cancer auxiliary diagnosis composition comprises a circular RNA ALG8 primer and a circular RNA CAMTA1 primer, circALG8 and circCAMTA1 can be used as markers of early non-small cell lung cancer liquid biopsy, and the non-small cell lung cancer auxiliary diagnosis composition can be applied to diagnosis of non-small cell lung cancer. According to the present invention, with the application of the circALG8 primer and the circCAMTA1 primer, the plasma circALG8 and circCAMTA1 combined diagnosis model can be successfully constructed, the NSCLC patient and the healthy control can be effectively distinguished, the area under the curve is up to 0.8987 when the circALG8 primer and the circCAMTA1 primer are combined to identify the efficiency of the early NSCLC, the identification result has extremely high accuracy, the diagnosis accuracy is significantly improved, the sensitivity reaches 91.78%, and the specificity reaches 75.53%.

The invention provides an alkaloid compound as well as a preparation method and an application thereof in tumor resistance. The alkaloid compound provided by the invention shows a remarkable cytotoxic effect on human non-small cell lung cancer cells A549, mouse lung adenocarcinoma cells Lewis, human triple negative breast cancer cells MDA-MB-231 and mouse breast cancer cells 4T1, and can be used for preparing medicines for treating breast cancer, lung cancer and the like.

The invention discloses a coumarin KRAS-G12C inhibitor as well as preparation and application of the coumarin KRAS-G12C inhibitor. The coumarin compound disclosed by the invention has a remarkable inhibition effect on non-small cell lung cancer cells (NCI-H23 and NCI-H358) with high expression of KRAS-G12C and pancreatic cancer cells (MIAPaCa-2), is particularly used for preparing medicines for treating and / or preventing non-small cell lung cancer and pancreatic cancer, and has a good prospect of development and application of antitumor medicines.

The invention discloses a multifunctional nano delivery system based on targeted ferritin as well as a preparation method and application of the multifunctional nano delivery system. According to the system, traditional Chinese medicine active ingredients, namely neogambogic acid GNA, a photosensitizer Ce6 and ferritin targeting peptide HKN15 are integrated through a self-assembly technology, a synergistic treatment system integrating photodynamic therapy PDT and ferroptosis induction is constructed, and the treatment effect on non-small cell lung cancer NSCLC can be remarkably enhanced. According to the nano delivery system, precise targeting of a tumor site is achieved through the ferritin targeting peptide HKN15, and a double anti-tumor mechanism is formed by utilizing the photodynamic effect of the photosensitizer Ce6 and the ferroptosis induction effect of GNA. The preparation process is based on a molecular self-assembly principle, and has the advantages of high tumor accumulation efficiency, low system toxicity, remarkable tumor inhibition effect and the like, and an innovative solution is provided for precise treatment of the non-small cell lung cancer.

The invention discloses a pharmaceutical composition for treating non-small cell lung cancer and application of the pharmaceutical composition. The composition comprises an IGF2BP3 inhibitor and a platinum chemotherapeutic drug. According to the combined medication scheme, the IGF2BP3 function is inhibited to block an ATF4 survival promoting signal channel mediated by the IGF2BP3 function, a synergistic effect is generated with a DNA damage mechanism of platinum drugs, the anti-tumor effect can be remarkably enhanced, chemotherapy drug resistance can be effectively reversed, toxic and side effects are expected to be reduced, and the application prospect is wide. And a new strategy is provided for overcoming the treatment problem of the non-small cell lung cancer, especially platinum-resistant non-small cell lung cancer.

The invention discloses a construction method of a non-small cell lung cancer classification prediction model. The construction method comprises the following steps: S1, acquiring data of a training set sample and clinical feature data corresponding to the sample; s2, acquiring immune related gene data; s3, extracting prognosis genes related to non-small cell lung cancer metastasis traits and expression conditions of the prognosis genes from the data of the training set samples in the step S1, and intersecting the prognosis genes and the expression conditions of the prognosis genes with the immune related gene data in the step S2 to obtain intersection genes as candidate genes; s4, screening the candidate genes in the step S3 to obtain immune characteristic genes and expression conditions thereof; and S5, constructing a model based on the immune characteristic gene in the step S4 to obtain a classification prediction model. The method comprises the following steps: screening out key immune characteristic genes and expression conditions thereof by combining immune-related gene data, and constructing a classification prediction model according to the key immune characteristic genes; and inputting gene expression data of a to-be-detected sample into the classification prediction model to classify the to-be-detected sample to be high-risk or low-risk.

The invention belongs to the technical field of data processing, and particularly discloses a method and system for predicting the lifetime of a non-small cell lung cancer patient after radiotherapy, and the method comprises the steps: collecting multi-time-point imaging and hematology follow-up visit data of the patient after radiotherapy, building a longitudinal follow-up visit sequence, and mapping the longitudinal follow-up visit sequence to a unified time axis; determining a bimodal first-time significant improvement point through preset rule judgment, and constructing and standardizing an asynchronous index according to the bimodal first-time significant improvement point; then inputting a feature vector at a follow-up time point, encoding a bimodal sequence through a Transform time sequence encoder, and generating joint representation through cross-modal interaction; and finally, inputting the standardized asynchronous index, the joint representation and the clinical and radiotherapy characteristics into a DeepHit model, and outputting a patient survival distribution prediction result. According to the method, bimodal indexes can be accurately captured, time dislocation is improved, prediction accuracy and individualization degree are improved, and a reliable basis is provided for clinical prognosis evaluation.

The disclosure provides a method for treating a subject afflicted with a tumor derived from a small cell lung cancer (SCLC) having a high tumor mutational burden (TMB) status comprising administering to the subject a monotherapy comprising an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody. The present disclosure also provides a method for identifying a subject suitable for treatment with an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody comprising measuring a TMB status of a biological sample of the subject. A high TMB status identifies the patient as suitable for treatment with an anti-PD-1 antibody or antigen-binding portion thereof. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.

The invention discloses a human small cell lung cancer brain metastasis organoid culture medium and a culture method. According to the culture medium, an advanced DMEM / F12 culture medium is used as a basic culture medium, and the following components are added: 2 to 5 [mu] M of GlutaMax, 8 to 10 [mu] M of HEPES, 1 * to 2 * of B27, 500 [mu] M of SB202190, 5 to 10 [mu] M of Y-27632, 0.5 [mu] M of A83-01, 0.5 to 2 [mu] M of N-Acetyl-L-cysteine, 5 mM of Nicotinamide, 25 to 100 ng / ml of recombinant human FGF7, 100 to 500 ng / ml of recombinant human FGF10, 100 to 200 ng / ml of Human Noggin, 50 to 500 ng / ml of Human R-Spondin-1, 50 to 100 ng / ml of According to the culture method, TryPLE Express is used for dissociation, the time is short, the activity of dissociated single cells is high, and the success rate of organoid culture can be increased to the maximum extent. Meanwhile, by combining with a culture medium with an optimized formula proportion, formation and growth of brain metastatic organs of the human small cell lung cancer can be promoted, and the construction success rate is increased.

Disclosed herein are systems, methods, and compositions for treating a subject diagnosed with, or suffering from cancer. In some embodiments, the method comprises determining whether a tumor sample from the subject includes a cytotoxic gene signature, and treating the subject based on the determination. In some embodiments, the subject has or is suspected of having a loss of heterozygosity in human leukocyte antigen (HLA) class I genes. In some embodiments, the therapy comprises one or more checkpoint inhibitors. In some embodiments, the cancer is colorectal, uterine, stomach, lung, skin, head or neck, or non-small cell lung carcinoma.

The invention discloses a phosphorylated peptidomimetic compound and a medical application thereof. The invention provides a phosphorylated peptidomimetic compound with a novel structure. Activity research shows that the phosphorylated peptidomimetic compound has excellent Cbl-b inhibitory activity and is an effective Cbl-b inhibitor. Technicians in the field know that Cbl-b overexpression can inhibit T cell immune response, and inhibition of Cbl-b can activate killing of an immune system on tumor cells. Therefore, the phosphorylated peptidomimetic compound or pharmaceutically acceptable salts and solvates thereof provided by the invention can be developed and prepared into drugs for treating diseases (such as non-small cell lung cancer, breast cancer, prostate cancer, head and neck squamous cell carcinoma, liver cancer, pancreatic cancer, colorectal cancer, ovarian cancer and other tumors) treated or relieved by inhibiting Cbl-b (such as non-small cell lung cancer, breast cancer, prostate cancer, head and neck squamous cell carcinoma, liver cancer, pancreatic cancer, colorectal cancer, ovarian cancer and the like) the medicine prospect is promising.

The invention relates to the technical field of non-small cell lung cancer treatment, in particular to application of a novel epidermal growth factor receptor degradation protein hydrolysis targeting chimera DC1-206 in preparation of a medicine for treating EGFR mutant non-small cell lung cancer. The structure of the targeted chimera DC1-206 comprises an E3 ubiquitin ligase ligand, a target protein ligand EGFR-TKI and a Linker of a special structure for connecting two active ligands, a triad EGFR-PROTAC active drug molecule is finally formed, the target protein ligand of PROTAC is combined with a target protein in the body of a patient, and the targeted chimera DC1-206 can be used for preparing the targeted chimera DC1-206. According to the present invention, the E3 ubiquitin ligase ligand is combined with the substrate binding region of the E3 ubiquitin ligase in the cell, such that the target protein is pulled to the side of the E3 ubiquitin ligase through the Linker, the target protein is degraded by the UPS system, the lung cancer cell proliferation is effectively inhibited, the lung cancer cell apoptosis is promoted, and the efficient targeting tumor inhibition effect is achieved.

Disclosed is an anticancer composition using a flavone derivative. In the present invention, the flavone derivative exhibits cytotoxicity against: H827, H1299, H522, and A549, which are human non-small cell lung cancer cell lines; MCF-7, which is a human breast cancer cell line; and PANC-1, which is a human pancreatic cancer cell line, in a time-dependent manner and in a treatment concentration-dependent manner, and not only exhibits a synergistic effect when used in combination with other conventional anticancer agents, such as osimertinib, which is an anticancer agent targeting for lung cancer, tamoxifen, which is a hormone agent against breast cancer, and gemcitabine, which is a cytotoxic anticancer agent against pancreatic cancer, but also exhibits the effect of synergistically inhibiting the expression of HIF-1α when used alone or in combination with an existing anticancer agent.

The invention belongs to the technical field of radiooncology, artificial intelligence and medical image fusion, and particularly relates to a model construction method and system for predicting the radiation pneumonitis risk of a patient receiving immune combined radiotherapy. According to the method, for a non-small cell lung cancer patient receiving immune checkpoint inhibitor (ICIs) combined radiotherapy, clinical information and radiotherapy dose parameters of the patient are collected, a positioning CT image and dynamic immune factor data are simulated, multi-source features including radiomics features, an immune change curve and dose volume indexes are extracted, and a multi-modal fusion prediction model is constructed. The system integrates automatic data input, feature extraction, model training and risk output modules, can output individual radiation pneumonitis risk scores, provides risk grading and dose intervention suggestions, and has high prediction accuracy and clinical interpretability. The method can be widely applied to individualized risk management and precise treatment of non-small cell lung cancer immune combined radiotherapy patients.

The invention belongs to the technical field of biomedical detection, and discloses a nucleic acid aptamer, a nucleic acid aptamer derivative and application thereof. An aptamer DNA long single chain targeting DLL3 is screened through an exponential enrichment systematic evolution (SELEX) technology, sequence optimization is performed on the aptamer DNA long single chain to obtain another two short chains, the aptamer can specifically target tumor cell surface DLL3, and the aptamer and small cell lung cancer cells SHP77, H69 and the like with high expression of the DLL3 have a specific targeting recognition effect. The invention also discloses screening and optimization of the nucleic acid aptamer. The nucleic acid aptamer has the advantages of being high in affinity and specificity, free of immunogenicity, simple and stable in chemical synthesis, easy to store and mark and the like.

The invention discloses a pathological complete remission prediction method and device for non-small cell lung cancer neoadjuvant chemotherapy, and relates to the field of medical imagines.The method comprises the steps that a preoperative medical image and preoperative clinical data of a patient to be predicted are obtained; inputting the preoperative medical image and the preoperative clinical data into the trained pathology complete remission prediction model, and outputting a pathology complete remission result of the patient to be predicted by the pathology complete remission prediction model; the pathologic complete remission prediction model is constructed by using pre-treatment radiomics features, post-treatment radiomics features, difference-radiomics features, deep learning features and sample clinical data. Whether a non-small cell lung cancer patient receiving neoadjuvant chemotherapy reaches complete pathological remission or not is represented in a non-invasive mode, so that medical staff are assisted in formulating a personalized treatment scheme, and the clinical result of the patient is improved.

The invention provides application of a copper death inducer in preparation of a medicine for treating osimertinib-resistant non-small cell lung cancer, and belongs to the technical field of treatment of non-small cell lung cancer. According to the invention, through high-throughput drug screening, the copper death inducer copper diethyl dithiocarbamate (CuET) and osimertinib are combined for use, so that a remarkable synergistic anti-cancer effect is achieved; furthermore, through detection of a wild type and osimertinib drug-resistant cell line model, an osimertinib sensitive and drug-resistant patient-derived organoid and a mouse xenotransplantation model, it is found that the anti-tumor effect of osimertinib can be remarkably enhanced through copper death induction, and osimertinib drug resistance is overcome. According to the technical scheme provided by the invention, osimertinib drug-resistant non-small cell lung cancer cells can be effectively killed, the curative effect of osimertinib in sensitive and drug-resistant models is remarkably enhanced, and an application scene is provided for copper death in tumor treatment.

The invention belongs to the technical field of biology, and discloses a bioactive peptide which is a micromolecular anti-tumor bioactive peptide derived from sea cucumber, and the amino acid sequence of the bioactive peptide is FNPDTFD. Sephadex G-15 gel chromatography and mass spectrometry technologies are used for separating, purifying and structurally identifying the sea cucumber flower enzymolysis peptide, so that the small molecule peptide with a potential anti-tumor effect is obtained. A cell viability experiment verifies that the small molecule peptide can selectively inhibit the proliferation of EGFR mutant non-small cell lung cancer cells. Besides, molecular docking and protein immunoblotting results show that the peptide can be combined with EGFR mutant protein, and the activation of a downstream Akt / mTOR signal channel is inhibited by targeting the EGFR mutant protein, so that the biological activity of resisting the non-small cell lung cancer is exerted. The bioactive peptide not only has the potential of being developed into a new generation of EGFR targeting antitumor drugs, but also has wide application prospects in the field of functional health food. The preparation process is simple, and is suitable for industrial production and market popularization and application.

Provided herein are methods of treating advanced solid tumors in a subject in need thereof, for example, when the subject has advanced head and neck squamous cell carcinoma, colorectal cancer, non-small cell lung cancer, and bladder transitional cell carcinoma. Also provided herein are methods of treating leukemia (e.g., acute myelogenous leukemia) in a subject in need thereof.